Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration |
| |
Authors: | Timothy Y Y Lai Wai-Man Chan David T Liu Dennis S Lam |
| |
Institution: | (1) Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K Argyle Street, Hong Kong, SAR, People’s Republic of China |
| |
Abstract: | Background To report the efficacy of intravitreal injection of ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation
(RAP) in neovascular age-related macular degeneration (AMD).
Methods Case review of four consecutive patients who received 3 injections at monthly intervals of intravitreal ranibizumab injections
for RAP. The serial changes in best-corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography
(FA), and indocyanine green angiography (ICGA) are presented.
Results The baseline mean logMAR BCVA was 0.89 (Snellen equivalent of 20/155). After three injections of ranibizumab, all four patients
had visual improvement and the mean logMAR BCVA improved to 0.59 (Snellen equivalent of 20/78). The mean visual improvement
was 3.0 lines. All patients also had complete resolution of subretinal fluid after treatment, and the mean OCT central foveal
thickness reduced from 438 μm at baseline to 169 μm at 3 months. Follow-up FA and ICGA at 3 months showed absence of leakage
in three patients with minimal leakage in the remaining patient. One patient had recurrence of RAP at 8 months after commencement
of treatment, and repeat ranibizumab injection resulted in resolution of the subretinal fluid and pigment epithelial detachment
and visual improvement.
Conclusions Intravitreal ranibizumab injections appeared to be an effective treatment for RAP, resulting in visual gain and reduction
in macular thickness. Further long-term studies to evaluate the efficacy of intravitreal ranibizumab in RAP are warranted. |
| |
Keywords: | Retinal angiomatous proliferation Age-related macular degeneration Ranibizumab Anti-VEGF |
本文献已被 SpringerLink 等数据库收录! |
|